Condition
Glycogen Storage Disease Type V
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Completed4
Withdrawn1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT02919631Phase 2CompletedPrimary
Triheptanoin in Mc Ardle
NCT03844022CompletedPrimary
MRI in McArdle Disease (GSDV)
NCT02385162Withdrawn
Biomarker for Glycogen Storage Diseases (BioGlycogen)
NCT02635269Not ApplicableUnknown
Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy
NCT02432768Phase 2CompletedPrimary
The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)
NCT03112889Phase 2CompletedPrimary
Sodium Valproate for GSDV
Showing all 6 trials